Aliases & Classifications for Choreatic Disease

MalaCards integrated aliases for Choreatic Disease:

Name: Choreatic Disease 12 15 71
Chorea 12 74 53 29 6 15 71
Hereditary Chorea 12 29 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12859
ICD10 32 G25.5
UMLS 71 C0008489 C0699731 C4020858

Summaries for Choreatic Disease

Disease Ontology : 12 A movement disease characterized by brief, semi-directed, irregular movements that not repetitive or rhythmic, but appear to flow from one muscle to the next.

MalaCards based summary : Choreatic Disease, also known as chorea, is related to chorea, benign hereditary and chorea gravidarum, and has symptoms including ataxia, myoclonus and tremor. An important gene associated with Choreatic Disease is HTT (Huntingtin), and among its related pathways/superpathways are Parkinson disease and Beta-Adrenergic Signaling. The drugs Dopamine and Amantadine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Chorea (or choreia, occasionally) is an abnormal involuntary movement disorder, one of a group of... more...

Related Diseases for Choreatic Disease

Diseases related to Choreatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 582)
# Related Disease Score Top Affiliating Genes
1 chorea, benign hereditary 35.0 NKX2-1 ADCY5
2 chorea gravidarum 34.7 XK JRK DPYSL5
3 choreoacanthocytosis 33.6 XK VPS13A TBP JPH3 HTT FTL
4 huntington disease 33.5 XK VPS13A TBP JPH3 HTT DRD2
5 mcleod syndrome 33.0 XK VPS13A DRD2
6 dentatorubral-pallidoluysian atrophy 32.9 TBP JPH3 HTT
7 tardive dyskinesia 32.8 DRD3 DRD2
8 aceruloplasminemia 32.7 XK VPS13A FTL
9 huntington disease-like 2 32.6 XK VPS13A JPH3 HTT
10 spinocerebellar ataxia 1 32.6 TBP MIR9-1 HTT
11 obsessive-compulsive disorder 31.0 DRD4 DRD3 DRD2 DRD1
12 autosomal dominant cerebellar ataxia 30.5 TBP MIR9-1 JPH3 HTT
13 huntington disease-like 1 30.5 XK VPS13A TBP JPH3
14 tic disorder 30.4 SLC18A2 PNKD GYPE DRD5 DRD4 DRD3
15 basal ganglia disease 30.4 VPS13A GYPE FTL
16 attention deficit-hyperactivity disorder 30.4 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
17 supranuclear palsy, progressive, 1 30.4 IGLON5 HTT DRD5 DRD2
18 neurodegeneration with brain iron accumulation 1 30.3 XK VPS13A JPH3 FTL
19 early-onset schizophrenia 30.3 DRD2 DRD1
20 alcohol use disorder 30.3 DRD3 DRD2 DRD1
21 gilles de la tourette syndrome 30.3 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
22 neurodegeneration with brain iron accumulation 30.2 XK VPS13A JPH3 FTL
23 toxic encephalopathy 30.2 SLC18A2 MIR9-1 HTT
24 von economo's disease 30.2 IGLON5 DPYSL5
25 mental depression 30.2 DRD4 DRD3 DRD2 DRD1
26 neuroleptic malignant syndrome 30.2 DRD3 DRD2 DRD1
27 amphetamine abuse 30.1 SLC18A2 DRD5 DRD4
28 migraine with or without aura 1 30.1 PNKD DRD5 DRD4 DRD3 DRD2 DRD1
29 trichotillomania 30.1 DRD4 DRD3 DRD2
30 dyskinetic cerebral palsy 30.1 PNKD NKX2-1 JRK ADCY5
31 hemidystonia 30.1 PNKD JRK GYPE DRD2
32 focal hand dystonia 30.1 JRK DRD2
33 personality disorder 30.0 DRD4 DRD3 DRD2
34 mood disorder 29.9 SLC18A2 MIR9-1 DRD4 DRD3 DRD2 DRD1
35 focal dystonia 29.9 TBP PNKD JRK DRD5 DRD2 DRD1
36 movement disease 29.8 VPS13A SLC18A2 PNKD NKX2-1 MIR9-1 JRK
37 oculogyric crisis 29.8 DRD5 DRD4 DRD3 DRD2 DRD1
38 alcohol dependence 29.8 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
39 gastroparesis 29.8 DRD5 DRD4 DRD3 DRD2 DRD1
40 parkinson disease, late-onset 29.8 TBP SLC18A2 MIR9-1 HTT DRD5 DRD4
41 schizophrenia 29.7 TBP SLC18A2 MIR9-1 DRD5 DRD4 DRD3
42 lingual-facial-buccal dyskinesia 29.7 XK VPS13A SLC18A2 JRK DRD5 DRD4
43 dystonia 29.6 XK VPS13A TBP SLC18A2 PNKD NKX2-1
44 autism spectrum disorder 29.6 DRD5 DRD4 DRD3 DRD2 DRD1
45 bipolar disorder 29.5 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
46 whipple disease 29.5 IGLON5 DPYSL5
47 restless legs syndrome 29.5 TBP NKX2-1 FTL DRD5 DRD4 DRD3
48 autism 29.3 HTT DRD5 DRD4 DRD3 DRD2 DRD1
49 sydenham chorea 12.9
50 chorea, remitting, with nystagmus and cataract 12.4

Graphical network of the top 20 diseases related to Choreatic Disease:



Diseases related to Choreatic Disease

Symptoms & Phenotypes for Choreatic Disease

UMLS symptoms related to Choreatic Disease:


ataxia, myoclonus, tremor, clonus, involuntary movements, dystonia, athetosis, other symptoms involving nervous and musculoskeletal systems, muscular fasciculation, spasm, synkinesis, recurrent muscle twitches (symptom)

MGI Mouse Phenotypes related to Choreatic Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 ADCY5 DPYSL5 DRD1 DRD2 DRD3 DRD4
2 homeostasis/metabolism MP:0005376 9.77 ADCY5 DRD1 DRD2 DRD3 DRD4 FTL
3 nervous system MP:0003631 9.5 DPYSL5 DRD1 DRD2 DRD3 DRD4 DRD5

Drugs & Therapeutics for Choreatic Disease

Drugs for Choreatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Amantadine Approved Phase 4 768-94-5 2130
3
Levodopa Approved Phase 4 59-92-7 6047
4
Carbidopa Approved Phase 4 28860-95-9 34359
5
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
6 Carbidopa, levodopa drug combination Phase 4
7 Dihydroxyphenylalanine Phase 4
8 Psychotropic Drugs Phase 4
9 Dopamine Agents Phase 4
10 Antiparkinson Agents Phase 4
11 Anti-Infective Agents Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Antiviral Agents Phase 4
14 Analgesics Phase 4
15 Dopamine agonists Phase 4
16 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
17 Antidepressive Agents Phase 4
18 Neuroprotective Agents Phase 4
19 Monoamine Oxidase Inhibitors Phase 4
20 Protective Agents Phase 4
21
Tetrabenazine Approved, Investigational Phase 3 58-46-8 6018
22
Paroxetine Approved, Investigational Phase 3 61869-08-7 43815
23
Fluoxetine Approved, Vet_approved Phase 3 54910-89-3 3386
24
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
25
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
26 Dopamine Antagonists Phase 3
27 Antipsychotic Agents Phase 3
28 Adrenergic Agents Phase 3
29 Gastrointestinal Agents Phase 3
30 Antiemetics Phase 3
31 Tiapride Hydrochloride Phase 3
32 Serotonin Uptake Inhibitors Phase 3
33
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
34
Citalopram Approved Phase 2 59729-33-8 2771
35
Histamine Approved, Investigational Phase 2 51-45-6 774
36
Famotidine Approved Phase 2 76824-35-6 3325
37
Trihexyphenidyl Approved Phase 2 144-11-6, 58947-95-8 5572
38
Risperidone Approved, Investigational Phase 2 106266-06-2 5073
39
Natalizumab Approved, Investigational Phase 1, Phase 2 189261-10-7
40
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
41 Excitatory Amino Acid Antagonists Phase 2
42 Anti-Bacterial Agents Phase 2
43 penicillins Phase 2
44 Atomoxetine Hydrochloride Phase 2
45 Antacids Phase 2
46 Anti-Ulcer Agents Phase 2
47 Histamine Antagonists Phase 2
48
Histamine Phosphate Phase 2 51-74-1 65513
49 Histamine H2 Antagonists Phase 2
50 Cholinergic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
2 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
3 Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics Completed NCT00888186 Phase 4 levodopa/carbidopa
4 Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
5 A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea Completed NCT00219804 Phase 3 tetrabenazine or placebo
6 An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease Completed NCT01897896 Phase 3 SD-809
7 A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease Completed NCT01795859 Phase 3 SD-809;Placebo
8 Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study. Completed NCT00632645 Phase 3 Olanzapine;Xenazine;Tiapridal
9 Double-Blind, Randomised, Two-Armed Study for the Evaluation of Efficacy and Safety of Minocycline for Treatment Completed NCT00146809 Phase 3 Minocyline
10 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease Recruiting NCT04102579 Phase 3 Valbenazine;Placebo
11 A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents Active, not recruiting NCT03813238 Phase 3 Deutetrabenazine;Placebo
12 Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease Enrolling by invitation NCT04400331 Phase 3 Valbenazine
13 Trial of Kuvan™ (Sapropterin) Treatment in Patients With Lesch Nyhan Disease Withdrawn NCT00935753 Phase 2, Phase 3 sapropterin
14 Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01834053 Phase 1, Phase 2
15 Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements. Completed NCT03575676 Phase 2 SOM3355 100mg BID;SOM3355 200mg BID;Placebo BID
16 NMDA-Receptor Blockade in Huntington's Chorea Completed NCT00001930 Phase 2 Amantadine
17 A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART). Completed NCT01306929 Phase 2 pridopidine
18 A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease Completed NCT02197130 Phase 2 PF-02545920;PF-02545920
19 Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study Completed NCT00368849 Phase 2 atomoxetine;Matching Placebo
20 A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD) Completed NCT00271596 Phase 2 20mg daily citalopram;Placebo
21 An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease Completed NCT01937078 Phase 2 Famotidine
22 Childhood Hypertonia of Central Origin: An Open Label Trial of Anticholinergic Treatment Effects Completed NCT00122044 Phase 2 trihexyphenidyl
23 A Trial of Prophylaxis for the PANDAS Subgroup Completed NCT00001359 Phase 2 Penicillin or Placebo
24 Risperidone for the Treatment of Huntington's Disease Chorea Not yet recruiting NCT04201834 Phase 2 Risperidone
25 Clinical and Neurochemical Effects of Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis Not yet recruiting NCT04062331 Phase 1, Phase 2 Placebos
26 A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea Terminated NCT01019473 Phase 2 AFQ056;Placebo
27 An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021 Terminated NCT02342548 Phase 2 20 mg BID of PF-02545920
28 Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD Unknown status NCT00675077 Phase 1
29 Ursodiol in Huntington's Disease Unknown status NCT00514774 Phase 1 ursodiol;placebo
30 A Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196 Completed NCT01485965 Phase 1 SEN0014196
31 (+)-Alpha-Dihydrotetrabenazine Phase I Completed NCT02844179 Phase 1 HTBZ
32 An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients to Assess Pharmacokinetics, Candidate Pharmacodynamic Measures of Target Engagement and Disease Modulation as Well as Acute Phenotypical Effects Following Multiple Oral Doses of SEN0014196. Completed NCT01485952 Phase 1 SEN0014196 (Low Dose);SEN0014196 (High Dose);Placebo
33 The Effects of Music Therapy on Depression, Chorea and Other Symptoms of Huntington's Disease Completed NCT00178360 Phase 1
34 An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's Disease Recruiting NCT03764215 Phase 1 Nilotinib 150 MG
35 PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease Unknown status NCT02263430
36 Exploring Hypertonia in Children With Cerebral Palsy- a Population-based Approach. Unknown status NCT01744158
37 Deep Brain Stimulation in the Treatment of Intractable Movement Disorders ( Parkinson's Disease, Essential Tremors and Dystonia) Unknown status NCT03562403
38 Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases Unknown status NCT02340871
39 Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease Completed NCT01451463
40 Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea Completed NCT00615797 standard interventions penicillin VK and haloperidol
41 Characterization of Cardiac and Skeletal Myopathy, Risk Evaluation, and Phenotype-Genotype Correlation in Patients With Neuroacanthocytosis Completed NCT00007228
42 Plasma Adiponectin Levels and Relations With Cytokines in Children With Acute Rheumatic Fever Completed NCT01886846
43 Accelerated Diffusion MRI as a Potential Image Based Biomarker for Hungtington Disease Completed NCT01884181
44 Comparative 2-D Tumor Analysis in Familial Gliomas Completed NCT00125710
45 NIAID Clinical Center Genomics Opportunity Protocol Completed NCT02417766
46 Functional Neuro-Imaging of Strategy Use During Human Behavior Completed NCT00728741
47 Assessment The Effects of Proprioceptive Neuromuscular Facilitation, Myofascial Releasing Maneuvers and Home Exercises on Pain and Jaw Function in Patients With Bruxism Completed NCT03499665
48 I2PETPG - Quantification and Localisation of Imidazoline2 Binding Sites in a Group of Participants Diagnosed With Alzheimer's Disease Using 11C‑BU99008: a Positron Emission Tomography Study Completed NCT02874820 Early Phase 1 Idazoxan
49 I2PETHV - Quantification and Localisation of Imidazoline2 Binding Sites in Healthy Volunteers Using [11C]BU99008 a Positron Emission Tomography Study Completed NCT02323217 Early Phase 1 Idazoxan;Isocarboxazid
50 Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Recruiting NCT03599076

Search NIH Clinical Center for Choreatic Disease

Genetic Tests for Choreatic Disease

Genetic tests related to Choreatic Disease:

# Genetic test Affiliating Genes
1 Chorea 29
2 Hereditary Chorea 29

Anatomical Context for Choreatic Disease

MalaCards organs/tissues related to Choreatic Disease:

40
Brain, Testes, Heart, Thyroid, Globus Pallidus, Lung, Cortex

Publications for Choreatic Disease

Articles related to Choreatic Disease:

(show top 50) (show all 5608)
# Title Authors PMID Year
1
Sydenham chorea in a12- year old Saudi girl. 61
32566771 2020
2
The binding of the APT1 domains to phosphoinositides is regulated by metal ions in vitro. 61
32407779 2020
3
VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. 61
32454050 2020
4
Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians. 61
30849283 2020
5
Functional gait disorders: A sign-based approach. 61
32482839 2020
6
[Huntington's disease and Sydenham's chorea]. 61
32557468 2020
7
Novel mutation of the PRRT2 gene in two cases of paroxysmal kinesigenic dyskinesia: Two case reports. 61
32346475 2020
8
Huntington's disease as an unexpected cause of deafness with dystonia and chorea. 61
32534373 2020
9
Electroconvulsive therapy for severe depression, psychosis and chorea in a patient with Huntington's disease: case report and review of the literature. 61
32513333 2020
10
Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD). 61
32229581 2020
11
Phenotypic variability in chorea-acanthocytosis associated with novel VPS13A mutations. 61
32494755 2020
12
Subthalamic nucleus deep brain stimulation in two siblings with chorea-acanthocytosis. 61
31938984 2020
13
Characteristics of Children with Acute Rheumatic Carditis from a High-Incidence Region: Importance of Unexplained Worsening of Functional Class. 61
32526745 2020
14
Allan-Herndon-Dudley-Syndrome: Considerations about the Brain Phenotype with Implications for Treatment Strategies. 61
32242326 2020
15
New Onset Chorea in a Previously Healthy 7-Year-Old. 61
32534792 2020
16
Preliminary data on prednisone effectiveness in children with Sydenham chorea. 61
31965299 2020
17
ACR Appropriateness Criteria® Movement Disorders and Neurodegenerative Diseases. 61
32370961 2020
18
Functional movement disorders. 61
31606137 2020
19
Early-Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease. 61
31922295 2020
20
[Huntington's disease with childhood and adolescent onset: course of disease, clinical presentation and diagnostic challenges]. 61
32369858 2020
21
Pridopidine in the treatment of Huntington's disease. 61
32083454 2020
22
Hyperpolarization of the subthalamic nucleus alleviates hyperkinetic movement disorders. 61
32427942 2020
23
Benign hereditary chorea: From benign to serious. 61
31983472 2020
24
Clinical manifestation of non-ketotic hyperglycemia chorea: A case report and literature review. 61
32481362 2020
25
Chorea is a pleiotropic clinical feature of mutated fused-in-sarcoma in amyotrophic lateral sclerosis. 61
32116048 2020
26
Decreased Na+/K+ ATPase Expression and Depolarized Cell Membrane in Neurons Differentiated from Chorea-Acanthocytosis Patients. 61
32439941 2020
27
Chorea-acanthocytosis with a novel mutation in the vacuolar protein sorting 13 homolog a gene: A case report. 61
32088470 2020
28
Optic Atrophy and Generalized Chorea in a Patient Harboring an OPA10/RTN4IP1 Pathogenic Variant. 61
32392611 2020
29
Serum periostin levels in acute rheumatic fever: is it useful as a new biomarker? 61
31648625 2020
30
Are there any novel markers in acute rheumatic fever: neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio. 61
32364093 2020
31
Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of hyperkinetic movement associated with Huntington's disease: Pharmacokinetic and brain delivery study. 61
32439327 2020
32
Methylphenidate-induced Exacerbation of Chorea in a Child Resolved with Switching to Atomoxetine. 61
32329313 2020
33
Generalized Chorea and JAK2V617F Mutation-Positive Myeloproliferative Disorders. 61
32373666 2020
34
Efficacy of Levetiracetam in the Treatment of Sydenham Chorea. 61
32445412 2020
35
A Case of Generalized Chorea Presenting as an Early Feature of Fragile-X Associated Tremor/Ataxia Syndrome. 61
32373667 2020
36
The GRIA3 c.2477G > A Variant Causes an Exaggerated Startle Reflex, Chorea, and Multifocal Myoclonus. 61
32369665 2020
37
131 A Marionettist Pulling My Strings: A Case of Buprenorphine-induced Chorea. 61
32331089 2020
38
Is high blood concentration of ceftriaxone the only cause of chorea-like symptoms in a patient undergoing hemodialysis. 61
32327333 2020
39
The impact of proteostasis dysfunction secondary to environmental and genetic causes on neurodegenerative diseases progression and potential therapeutic intervention. 61
32072427 2020
40
152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents. 61
32331029 2020
41
The following abstracts were presented as posters at the 2019 NEI Congress. 61
32331094 2020
42
Whole exome sequencing identifies a homozygous POLG2 missense variant in an adult patient presenting with optic atrophy, movement disorders, premature ovarian failure and mitochondrial DNA depletion. 61
31778857 2020
43
Spinocerebellar ataxia type 48: last but not least. 61
32342324 2020
44
Coeliac disease presenting with chorea. 61
31780451 2020
45
Voluntary Inhibitory Control of Chorea: A Case Series. 61
32258230 2020
46
Chorea-like symptoms and high blood concentration of ceftriaxone in a patient undergoing hemodialysis: A case report. 61
31680037 2020
47
Chorea/ballism secondary to non-ketotic hyperglycaemia: Report of 4 cases. 61
29277521 2020
48
Complex pathophysiology of non-ketotic hyperglycemic chorea-ballism with atypical findings on brain magnetic resonance imaging. 61
31954355 2020
49
Movement disorders in patients with alternating hemiplegia: "Soft" and "stiff" at the same time. 61
32123049 2020
50
Pediatric APS: State of the Art. 61
32124078 2020

Variations for Choreatic Disease

Expression for Choreatic Disease

Search GEO for disease gene expression data for Choreatic Disease.

Pathways for Choreatic Disease

Pathways related to Choreatic Disease according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.94 TBP SLC18A2 HTT DRD2 DRD1 ADCY5
2
Show member pathways
12.55 DRD5 DRD4 DRD3 DRD2 DRD1
3
Show member pathways
12.47 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1
4 12.07 DRD5 DRD2 DRD1 ADCY5
6 11.79 DRD5 DRD4 DRD3 DRD2 DRD1 ADCY5
7
Show member pathways
11.78 SLC18A2 DRD2 DRD1 ADCY5
8
Show member pathways
11.72 DRD4 DRD2 DRD1
9
Show member pathways
11.67 SLC18A2 DRD4 DRD3 DRD2
10 11.6 DRD2 DRD1 ADCY5
11
Show member pathways
11.6 DRD5 DRD4 DRD3 DRD2 DRD1
12
Show member pathways
10.46 SLC18A2 DRD5 DRD4 DRD3 DRD2 DRD1

GO Terms for Choreatic Disease

Cellular components related to Choreatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 SLC18A2 GYPE DRD5 DRD4 DRD3 DRD2
2 dendrite GO:0030425 9.77 HTT DRD4 DRD2 DRD1 DPYSL5
3 synaptic vesicle membrane GO:0030672 9.61 SLC18A2 DRD3 DRD2
4 GABA-ergic synapse GO:0098982 9.58 DRD3 DRD2 DRD1
5 ciliary membrane GO:0060170 9.5 DRD5 DRD2 DRD1
6 9+0 non-motile cilium GO:0097731 9.46 DRD5 DRD1
7 cell GO:0005623 9.36 XK VPS13A JPH3 HTT FTL DRD5
8 non-motile cilium GO:0097730 9.33 DRD5 DRD2 DRD1
9 dopaminergic synapse GO:0098691 9.13 SLC18A2 DRD3 DRD2

Biological processes related to Choreatic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.99 DRD5 DRD3 DRD2 DRD1
2 cellular calcium ion homeostasis GO:0006874 9.91 XK DRD5 DRD4 DRD3
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.89 DRD5 DRD1 ADCY5
4 response to toxic substance GO:0009636 9.88 SLC18A2 DRD3 DRD2
5 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.88 DRD5 DRD3 DRD2 DRD1
6 learning GO:0007612 9.85 JPH3 DRD3 DRD1
7 social behavior GO:0035176 9.83 VPS13A DRD4 DRD3
8 visual learning GO:0008542 9.83 DRD3 DRD2 DRD1
9 response to cocaine GO:0042220 9.83 DRD5 DRD3 DRD2 DRD1
10 activation of adenylate cyclase activity GO:0007190 9.82 DRD5 DRD1 ADCY5
11 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.81 DRD3 DRD2 DRD1
12 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.8 DRD5 DRD3 DRD2 DRD1
13 associative learning GO:0008306 9.79 DRD5 DRD2 DRD1
14 negative regulation of blood pressure GO:0045776 9.79 DRD5 DRD3 DRD2
15 negative regulation of protein secretion GO:0050709 9.77 DRD4 DRD3 DRD2
16 arachidonic acid secretion GO:0050482 9.76 DRD4 DRD3 DRD2
17 behavioral response to cocaine GO:0048148 9.76 DRD4 DRD3 DRD2 DRD1
18 negative regulation of voltage-gated calcium channel activity GO:1901386 9.74 DRD4 DRD3 DRD2
19 prepulse inhibition GO:0060134 9.73 DRD3 DRD2 DRD1
20 dopamine metabolic process GO:0042417 9.73 DRD4 DRD3 DRD2 DRD1
21 behavioral response to ethanol GO:0048149 9.72 DRD4 DRD3 DRD2
22 transmission of nerve impulse GO:0019226 9.71 DRD5 DRD1
23 negative regulation of cytosolic calcium ion concentration GO:0051481 9.71 DRD3 DRD2
24 long-term synaptic depression GO:0060292 9.71 DRD5 DRD1
25 regulation of dopamine metabolic process GO:0042053 9.71 PNKD DRD4 DRD1
26 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.71 DRD5 DRD3 DRD2 DRD1
27 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.7 DRD3 DRD2
28 positive regulation of renal sodium excretion GO:0035815 9.7 DRD3 DRD2
29 grooming behavior GO:0007625 9.7 DRD2 DRD1
30 G protein-coupled receptor internalization GO:0002031 9.69 DRD3 DRD2
31 striatum development GO:0021756 9.69 DRD2 DRD1
32 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.69 DRD4 DRD3
33 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.69 DRD3 DRD2 DRD1
34 regulation of potassium ion transport GO:0043266 9.68 DRD3 DRD2
35 peristalsis GO:0030432 9.68 DRD2 DRD1
36 mating behavior GO:0007617 9.67 DRD5 DRD1
37 cellular response to catecholamine stimulus GO:0071870 9.67 DRD5 DRD1
38 cerebral cortex GABAergic interneuron migration GO:0021853 9.67 DRD2 DRD1
39 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.67 DRD5 DRD3 DRD1 ADCY5
40 dopamine transport GO:0015872 9.66 SLC18A2 DRD1
41 regulation of neurotransmitter uptake GO:0051580 9.65 DRD3 DRD2
42 response to histamine GO:0034776 9.65 DRD4 DRD3 DRD2
43 dopamine receptor signaling pathway GO:0007212 9.65 DRD5 DRD4 DRD3 DRD2 DRD1
44 negative regulation of dopamine receptor signaling pathway GO:0060160 9.64 DRD3 DRD2
45 regulation of locomotion involved in locomotory behavior GO:0090325 9.63 DRD3 DRD2
46 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.63 DRD4 DRD2
47 acid secretion GO:0046717 9.62 DRD3 DRD2
48 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.62 DRD4 DRD3 DRD2 ADCY5
49 sensitization GO:0046960 9.6 DRD5 DRD1
50 synaptic transmission, dopaminergic GO:0001963 9.55 DRD5 DRD4 DRD3 DRD2 DRD1

Molecular functions related to Choreatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.54 DRD4 DRD3 DRD2
2 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD4 DRD3 DRD2
4 dopamine binding GO:0035240 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
5 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.32 DRD5 DRD1
6 dopamine neurotransmitter receptor activity GO:0004952 9.02 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Choreatic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....